Protocol Ledger

NCT06701812 · Phase II · RECRUITING

Digoxin Medulloblastoma Study

Interventional Phase II clinical trial protocol NCT06701812 sponsored by H. Lee Moffitt Cancer Center and Research Institute in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-01-15 Enrollment: 23 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06701812
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)23 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06701812
Protocol FieldVerified Registry Value
NCT IdentifierNCT06701812
Consolidated Lead SponsorH. Lee Moffitt Cancer Center and Research Institute
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment23 participants (ESTIMATED)
Registered Start Date2026-01-15
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06701812
Hospital Research SiteLocationSite Profile
Connecticut Children's Medical CenterHartford, CTOpen Hospital Dossier ->
Children's National Medical CenterWashington D.C, DCOpen Hospital Dossier ->
University of MiamiMiami, FLOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Moffitt Cancer Center across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI